WHO backs use of GLP-1 drugs for weight loss, Pg12

Key Highlights:

• The World Health Organization (WHO) issued global guidelines on December 1 supporting the use of glucagon-like peptide-1 (GLP-1) therapies for treating obesity in adults.
• The guidelines emphasize equitable access to these therapies as part of a comprehensive approach to combatting obesity.
• The WHO recognizes the effectiveness of GLP-1 drugs and their potential impact on the global economic costs of obesity, projected to reach $3 trillion annually by 2030.
• Recommendations state that GLP-1 therapies may be used by adults, excluding pregnant women, for long-term obesity treatment, alongside intensive behavioral interventions.

Detailed Insights:

• The WHO's recommendation is conditional due to limited data on long-term efficacy, safety, outcomes upon discontinuation, and the high cost of GLP-1 drugs, making them inaccessible to many.
• Obesity is recognized as a complex chronic disease driving noncommunicable diseases like cardiovascular diseases, type 2 diabetes, and certain cancers, while also worsening outcomes for infectious disease patients.
• Experts emphasize that GLP-1 therapies should galvanize efforts to build a fair, integrated, and sustainable obesity ecosystem with equitable access to comprehensive disease management, health promotion, and prevention policies.
• For countries like India, the high cost of these drugs is a significant barrier, necessitating efforts towards insurance coverage and the development of generics to ensure affordability and wider accessibility.
• The guidelines stress that GLP-1 drugs are not a standalone solution and must be accompanied by consistent diet and exercise, especially for those who are not morbidly obese.

Key Concepts Involved:

• Obesity: A complex chronic disease involving excessive body fat accumulation that presents a risk to health.
• GLP-1 Therapies: A class of drugs that mimic the glucagon-like peptide-1 hormone, used to treat type 2 diabetes and obesity.
• Equitable Access: Ensuring fair and just access to healthcare resources and treatments, regardless of socioeconomic status or other factors.